kŽ¡—ÃKƒCƒhƒ‰ƒCƒ“l
1j
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents: October 10, 2006 ihttp://aidsinfo.nih.gov/j
2j
Scott M. Hammer et al. : Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA Panel. JAMA 296i7j, 827-843, 2006
3j
British HIV Association iBHIVAj guidelines for the treatment of HIV-infected adults with antiretroviral therapy: 2006 ihttp://www.bhiva.org/j
4j
RHIVŽ¡—ÃKƒCƒhƒ‰ƒCƒ“i2007”N3ŒŽj•½¬18”N“x Œú¶˜J“­È‰ÈŠwŒ¤‹†”ï•â•‹àƒGƒCƒY‘ÎôŒ¤‹†Ž–‹Æ u•ž–òƒAƒhƒqƒAƒ‰ƒ“ƒX‚ÌŒüãE ˆÛŽ‚ÉŠÖ‚·‚錤‹†v”Ç
k¬Ž™‚ÌŽ¡—Ãl
5j
Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection: October 26, 2006 ihttp://aidsinfo.nih.gov/j
k”D•w‚ÌŽ¡—Ãl
6j
Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States:
November 2, 2007 ihttp://aidsinfo.nih.gov/j
k–òܑϫl
7j
Johnson VA et al. : Update of the drug resistance mutations in HIV-1. Topics in HIV. Medicine 15i4j, 119-125, 2007
ihttp://www.iasusa.org/resistance_mutations/resistance.pdfj
8j
Mallal S et al.: Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. The Lancet 359, 727-732, 2002



–ß‚é